{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:02:27Z","timestamp":1776772947906,"version":"3.51.2"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000150","name":"Canadian Breast Cancer Research Alliance","doi-asserted-by":"publisher","award":["12345"],"award-info":[{"award-number":["12345"]}],"id":[{"id":"10.13039\/501100000150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Annual breast magnetic resonance imaging (MRI) plus mammography is the standard of care for screening women with inherited BRCA1\/2 mutations. However, long-term breast cancer-related mortality with screening is unknown. Between 1997 and June 2011, 489 previously unaffected BRCA1\/2 mutation carriers aged 25 to 65 years were screened with annual MRI plus mammography on our study. Thereafter, participants were eligible to continue MRI screening through the high-risk Ontario Breast Screening Program. In 2019, our data were linked to the Ontario Cancer Registry of Cancer Care Ontario to identify all incident cancers, vital status and causes of death. Observed breast cancer mortality was compared to expected mortality for age-matched women in the general population. There were 91 women diagnosed with breast cancer (72 invasive and 19 ductal carcinoma in situ (DCIS)) with median follow-up 7.4 (range: 0.1 to 19.2) years. Four deaths from breast cancer were observed, compared to 2.0 deaths expected (standardized mortality ratio (SMR) 2.0, p = 0.14). For the 489 women in the study, the probability of not dying of breast cancer at 20 years from the date of the first MRI was 98.2%. Annual screening with MRI plus mammography is a reasonable option for women who decline or defer risk-reducing mastectomy.<\/jats:p>","DOI":"10.3390\/cancers12113479","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T08:18:23Z","timestamp":1606119503000},"page":"3479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-6845","authenticated-orcid":false,"given":"Ellen","family":"Warner","sequence":"first","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald B.","family":"Plewes","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Hill","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrina A.","family":"Causer","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-2219","authenticated-orcid":false,"given":"Jean","family":"Seely","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Ottawa, Ottawa, ON K1N 6N5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta A.","family":"Jong","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Lenkov","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Elser","sequence":"additional","affiliation":[{"name":"Marvelle Koffler Breast Centre, Mt. Sinai Hospital, Toronto, ON M5G 1X5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Crystal","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, University Health Network, Toronto, ON M5T 1W7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-9915","authenticated-orcid":false,"given":"Martin J.","family":"Yaffe","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasily","family":"Giannakeas","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, University of Toronto, Toronto, ON M5G 1N8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, University of Toronto, Toronto, ON M5G 1N8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, University of Toronto, Toronto, ON M5G 1N8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chen, J., Bae, E., Zhang, L., Hughes, K., Parmigiani, G., Braun, D., and Rebbeck, T.R. (2020). Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1\/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr., 4.","DOI":"10.1093\/jncics\/pkaa029"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref_4","first-page":"CD002748","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.2018.18942","article-title":"Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion","volume":"321","author":"Domchek","year":"2019","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/cancers10120477","article-title":"Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer","volume":"10","author":"Warner","year":"2018","journal-title":"Cancers"},{"key":"ref_8","unstructured":"NICE Clinical Guideline (2020, October 07). Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer. Available online: www.nice.org.uk\/guidance\/cg164."},{"key":"ref_9","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2020, October 07). (NCCN Guidelines): Genetic\/Familial High Risk Assessment: Breast, Ovarian and Pancreatic. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Cardoso","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_11","unstructured":"Cancer Care Ontario Clinical Practice Guideline (2020, October 07). Magnetic Resonance Imaging Screening of Women at High Risk for Breast Cancer v.3. Available online: www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/2051."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/jnci\/djz079","article-title":"Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program","volume":"112","author":"Chiarelli","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11547-017-0757-3","article-title":"Gadolinium retention in the body: What we know and what we can do","volume":"122","author":"Tedeschi","year":"2017","journal-title":"Radiol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Jager","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1158\/1078-0432.CCR-07-0689","article-title":"A BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, UK, and Canadian MRI screening trials","volume":"13","author":"Obdeijn","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/ijc.29534","article-title":"Survival benefit in women with BRCA1mutation or familial risk in the MRI screening study (MRISC)","volume":"137","author":"Saadatmand","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10549-014-2931-9","article-title":"MRI breast screening in high-risk women: Cancer detection and survival analysis","volume":"145","author":"Gareth","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2020.2059","article-title":"Presymptomatic awareness of germline pathogenic BRCA Variants and associated outcomes in women with Breast Cancer","volume":"6","author":"Hadar","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10689-019-00142-8","article-title":"Should unaffected female BRCA2 pathogenic variant mutation carriers be told there is little or no advantage from risk reducing mastectomy?","volume":"18","author":"Evans","year":"2019","journal-title":"Fam. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.2015.127","article-title":"Prognosis of metastatic breast cancer: Are there differences between patients with de novo and recurrent metastatic breast cancer?","volume":"112","author":"Lobbezoo","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-017-4122-y","article-title":"Breast cancer screening of pregnant and breastfeeding women with BRCA mutations","volume":"162","author":"Carmichael","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-18-0200","article-title":"Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers","volume":"25","author":"Guindalini","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2015.33.15_suppl.tps1109","article-title":"OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Tutt","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lee, Y.-J., Lee, S.-W., Kim, K.-R., Jung, K.-H., Lee, J.-W., and Kim, Y.-M. (2017). Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: Significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. J. Gynecol. Oncol., 28.","DOI":"10.3802\/jgo.2017.28.e3"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study","volume":"26","author":"Kauff","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-020-1247-4","article-title":"Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Mavaddat","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_29","first-page":"1870834","article-title":"Primary Peritoneal Cancer Two Decades after a Bilateral Salpingo-Oophorectomy","volume":"2019","author":"Rodowa","year":"2019","journal-title":"Case Rep. Obstet. Gynecol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMe1914488","article-title":"Personalized medicine for primary treatment of serous ovarian cancer","volume":"381","author":"Longo","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:35:54Z","timestamp":1760178954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113479"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113479","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]}}}